Quatresooz Pascale, Hermanns-Lê Trinh, Piérard Gérald E, Humbert Philippe, Delvenne Philippe, Piérard-Franchimont Claudine
Department of Dermatopathology, University Hospital of Liège, 4000 Liège, Belgium.
J Biomed Biotechnol. 2012;2012:147413. doi: 10.1155/2012/147413. Epub 2012 Jun 12.
Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.
银屑病是一种慢性复发性免疫炎症性皮肤病，通常与全身性合并症相关。白细胞介素（IL）-12和IL-23的致病重要性毋庸置疑，辅助性T细胞（Th）1和Th17细胞也参与其中。IL-12和IL-23共有的p40亚基以及IL-23 p19亚基上调，但IL-12 p35亚基表达未增加。这表明在银屑病斑块的发病机制中，IL-23似乎比IL-12参与程度更高。乌司奴单抗是一种免疫球蛋白（Ig）G1类的全人单克隆抗体，靶向IL-12和IL-23共有的p40亚基，从而抑制IL-12和IL-23受体介导的信号传导。乌司奴单抗是近期用于治疗银屑病、自身免疫性关节炎和炎症性肠病的生物疗法之一。
